GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » Asset Turnover

China Resources Pharmaceutical Group (HKSE:03320) Asset Turnover : 0.47 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. China Resources Pharmaceutical Group's Revenue for the six months ended in Dec. 2023 was HK$127,025 Mil. China Resources Pharmaceutical Group's Total Assets for the quarter that ended in Dec. 2023 was HK$272,986 Mil. Therefore, China Resources Pharmaceutical Group's Asset Turnover for the quarter that ended in Dec. 2023 was 0.47.

Asset Turnover is linked to ROE % through Du Pont Formula. China Resources Pharmaceutical Group's annualized ROE % for the quarter that ended in Dec. 2023 was 4.50%. It is also linked to ROA % through Du Pont Formula. China Resources Pharmaceutical Group's annualized ROA % for the quarter that ended in Dec. 2023 was 0.84%.


China Resources Pharmaceutical Group Asset Turnover Historical Data

The historical data trend for China Resources Pharmaceutical Group's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group Asset Turnover Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.12 1.00 1.04 1.00 1.05

China Resources Pharmaceutical Group Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.50 0.50 0.54 0.47

Competitive Comparison of China Resources Pharmaceutical Group's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Pharmaceutical Group's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's Asset Turnover distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's Asset Turnover falls into.



China Resources Pharmaceutical Group Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

China Resources Pharmaceutical Group's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=267651.942/( (240690.407+269912.139)/ 2 )
=267651.942/255301.273
=1.05

China Resources Pharmaceutical Group's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=127025.342/( (276059.334+269912.139)/ 2 )
=127025.342/272985.7365
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


China Resources Pharmaceutical Group  (HKSE:03320) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

China Resources Pharmaceutical Group's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=2281.514/50647.168
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(2281.514 / 254050.684)*(254050.684 / 272985.7365)*(272985.7365/ 50647.168)
=Net Margin %*Asset Turnover*Equity Multiplier
=0.9 %*0.9306*5.39
=ROA %*Equity Multiplier
=0.84 %*5.39
=4.50 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

China Resources Pharmaceutical Group's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=2281.514/272985.7365
=(Net Income / Revenue)*(Revenue / Total Assets)
=(2281.514 / 254050.684)*(254050.684 / 272985.7365)
=Net Margin %*Asset Turnover
=0.9 %*0.9306
=0.84 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) net income data. The Revenue data used here is two times the semi-annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


China Resources Pharmaceutical Group Asset Turnover Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Pharmaceutical Group (HKSE:03320) Business Description

Traded in Other Exchanges
Address
26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG
CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.
Executives
Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines